Anupam Rama

Jonathan Chang

Yigal Nochomovitz

Michael Yee

Linhai Zhao

Li Watsek

Louise Chen

Po Han Lin

Jack Lin

Lin Hisao

Li Wang Watsek

Rebecca Liang

Ziyi Chen

- Zai Lab will present updated data from its global **Phase 1 trial of zocilurtatug pelitecan (zoci)**, a DLL3-targeted antibody-drug conjugate (ADC) for extensive-stage small cell lung cancer (ES-SCLC), at the **AACR-NCI-EORTC International Conference** from **October 22-26, 2025**.  **[1704292_97a3d209bd3b4dd7b1dd571345cd9cea_0]** 
- The company is **on track to initiate a Phase 3 registrational study** for zoci in previously treated SCLC by year-end.  **[1704292_97a3d209bd3b4dd7b1dd571345cd9cea_0]** 
- Zai Lab will host an **investor conference call and webcast** on **October 24, 2025**, to discuss the updated zoci data and clinical development plans.  **[1704292_97a3d209bd3b4dd7b1dd571345cd9cea_0]** 
- Zoci received **Orphan Drug Designation from the U.S. FDA in January 2025** for its potential to treat SCLC.  **[1704292_97a3d209bd3b4dd7b1dd571345cd9cea_1]**

Zai Lab Announces Oral Presentation of Zocilurtatug Pelitecan Data at 2025 AACR-NCI-EORTC Conference

Zai Lab (ZLAB)